OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Facebook

RSS

Youtube

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

February, 2025

Insight

Vivek Subbiah: Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic.

Photo taken from Vivek Subbiah/LinkedIn.

Oct 5, 2023, 17:42

Vivek Subbiah: Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at The Sarah Cannon Research Institute, on LinkedIn:

“ICYMI from the latest issue—of American Association for Cancer Research Journal Cancer Discovery, pleased to share our paper “RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations”. Elegant bench to bedside precision medicine work from Relay Therapeutics and superb investigators from multiple sites.

Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic. So thankful for the patients and caregivers who were motivated to enroll on clinical trials. Thankful to all the trial staff.”

For the article click here.
Source: Vivek Subbiah/LinkedIn

American Association for Cancer Research Journal cancer clinical trials FGFR2 Alterations ICYMI OncoDaily Oncology Pandemic patient Resistance mutations Trial staff Vivek Subbiah

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity